Clinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in Schizophrenia
Not Applicable
Completed
- Conditions
- cognitive deficits in patients with schizophreniapsychotic symptoms in patients with schizophreniaMental Health - Schizophrenia
- Registration Number
- ACTRN12608000461392
- Lead Sponsor
- niversity of New South Wales
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Male and female patients with schizophrenia between the ages of 18 and 45 who have been receiving any antipsychotic medication for at least one year can participate.
Exclusion Criteria
Any patients with a psychiatric diagnosis other than schizophrenia or a history of substance dependence (within past 5 years), head injuries with loss of consciousness, seizures, central nervous system infection, diabetes, hypertension, lactose intolerance, superficial thrombophlebitis (pain and inflammation in a vein just under the skin), thromboembolic disease (blood clotting disease), congestive heart failure, or who have had reactions to raloxifene will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Verbal Fluency Controlled Oral Word Association Test[baseline, week 6, week 13];verbal immediate and delayed story recall Wechlser Memory Scale III[baseline, week 6, week 13];working memory Letter-Number Sequencing Wechsler Adult Intelligence Scale III[baseline, week 6, week 13]
- Secondary Outcome Measures
Name Time Method positive and negative symptoms assessed using Positive and Negative Symptom Scale (PANSS) scores[baseline, week 6, week 13]